Apogee Therapeutics (NASDAQ:APGE) Given Outperform Rating at Wedbush

Wedbush reissued their outperform rating on shares of Apogee Therapeutics (NASDAQ:APGE - Free Report) in a research report sent to investors on Monday morning,RTT News reports. The firm currently has a $90.00 price target on the stock. Wedbush also issued estimates for Apogee Therapeutics' Q1 2025 earnings at ($1.24) EPS, Q2 2025 earnings at ($1.26) EPS, Q3 2025 earnings at ($1.21) EPS, Q4 2025 earnings at ($1.21) EPS, FY2025 earnings at ($4.92) EPS, FY2026 earnings at ($5.07) EPS, FY2027 earnings at ($5.56) EPS and FY2028 earnings at ($7.00) EPS.

APGE has been the topic of several other reports. Canaccord Genuity Group initiated coverage on Apogee Therapeutics in a research report on Monday, November 25th. They issued a "buy" rating and a $89.00 price target on the stock. Guggenheim reaffirmed a "buy" rating on shares of Apogee Therapeutics in a report on Monday, February 10th. Finally, Canaccord Genuity Group assumed coverage on shares of Apogee Therapeutics in a research note on Monday, November 25th. They set a "buy" rating and a $89.00 price target for the company. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $88.83.

Apogee Therapeutics Trading Up 12.8 %

NASDAQ APGE traded up $4.01 during trading on Monday, reaching $35.44. 1,063,358 shares of the company's stock were exchanged, compared to its average volume of 574,506. Apogee Therapeutics has a fifty-two week low of $29.10 and a fifty-two week high of $72.29. The company's fifty day simple moving average is $39.35 and its 200-day simple moving average is $47.10. The firm has a market capitalization of $1.60 billion, a PE ratio of -14.64 and a beta of 2.46.

Remove Ads

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($1.19) EPS for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.25). Equities analysts forecast that Apogee Therapeutics will post -3.09 EPS for the current fiscal year.

Insider Activity at Apogee Therapeutics

In related news, CEO Michael Thomas Henderson sold 15,000 shares of the firm's stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $48.85, for a total value of $732,750.00. Following the completion of the sale, the chief executive officer now owns 1,309,487 shares of the company's stock, valued at $63,968,439.95. This trade represents a 1.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Carl Dambkowski sold 4,540 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $48.76, for a total value of $221,370.40. Following the completion of the transaction, the insider now owns 258,073 shares in the company, valued at $12,583,639.48. The trade was a 1.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 42,145 shares of company stock valued at $1,897,799 in the last three months. Corporate insiders own 36.10% of the company's stock.

Institutional Investors Weigh In On Apogee Therapeutics

Several large investors have recently bought and sold shares of APGE. Wellington Management Group LLP grew its stake in Apogee Therapeutics by 35.7% in the third quarter. Wellington Management Group LLP now owns 4,814,400 shares of the company's stock valued at $282,798,000 after acquiring an additional 1,267,451 shares during the period. Mercer Global Advisors Inc. ADV acquired a new stake in Apogee Therapeutics in the fourth quarter valued at $32,621,000. Janus Henderson Group PLC raised its holdings in shares of Apogee Therapeutics by 141.7% in the 4th quarter. Janus Henderson Group PLC now owns 1,135,100 shares of the company's stock valued at $51,455,000 after purchasing an additional 665,543 shares during the period. Paradigm Biocapital Advisors LP lifted its stake in Apogee Therapeutics by 82.9% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 1,283,766 shares of the company's stock valued at $58,155,000 after purchasing an additional 581,949 shares during the last quarter. Finally, Jefferies Financial Group Inc. raised its stake in Apogee Therapeutics by 140.4% in the fourth quarter. Jefferies Financial Group Inc. now owns 887,497 shares of the company's stock valued at $40,204,000 after buying an additional 518,300 shares during the period. Institutional investors own 79.04% of the company's stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.